September 2023 –Cantex Pharmaceuticals and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma.
August 2023 –Cantex Pharmaceuticals announced the initiation of a Phase 2 clinical trial to assess the safety and effectiveness of Cantex’s azeliragon combined with stereotactic radiosurgery in patients with brain metastases.
August 2023 – Cantex Pharmaceuticals announced the publication in the peer-reviewed journal, npj Breast Cancer, reporting results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition. Cantex’s azeliragon is a RAGE inhibitor that is orally administered and taken once daily.